{"id":"NCT01181102","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2009-09","completion":"2010-02","firstPosted":"2010-08-13","resultsPosted":"2015-02-19","lastUpdate":"2019-03-05"},"enrollment":716,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"edoxaban","otherNames":[]},{"type":"DRUG","name":"enoxaparin sodium","otherNames":[]}],"arms":[{"label":"DU-176b","type":"EXPERIMENTAL"},{"label":"enoxaparin sodium","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.","primaryOutcome":{"measure":"Incidence of Subjects With Venous Thromboembolism Events.","timeFrame":"2 weeks","effectByArm":[{"arm":"DU-176b","deltaMin":7.4,"sd":null},{"arm":"Enoxaparin Sodium","deltaMin":13.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":3,"countries":["Japan","Taiwan"]},"refs":{"pmids":["27980462","27284271","25294589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":354},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Gamma-glutamyltransferase increased","blood urine present","Haemoglobin decreased"]}}